Episode 140: Shawn Gremminger on the Hidden Costs of the 340B Drug Pricing Program
Update: 2025-05-20
Description
In this episode of Listening In (With Permission), Shawn Gremminger, President and CEO of the National Alliance of Healthcare Purchaser Coalitions, joins Andréa Caballero of Catalyst for Payment Reform to dive into a pressing but often overlooked issue: the impact of the 340B Drug Pricing Program on pharmacy costs for employers and healthcare purchasers.
The 340B program, originally intended to support safety-net hospitals and community health centers, has expanded drastically over the years. Today, it's the second-largest drug purchasing program in the U.S., with an explosive $65 billion price tag. But what does this mean for employers and employees in the commercial market?
The 340B program, originally intended to support safety-net hospitals and community health centers, has expanded drastically over the years. Today, it's the second-largest drug purchasing program in the U.S., with an explosive $65 billion price tag. But what does this mean for employers and employees in the commercial market?
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
